NEFL and Alzheimer disease: Both previous EMIF-AD MBD GWAS focused on AD biomarkers measured in CSF and, among other findings, identified variants in TMEM106B as trans-pQTLs of CSF neurofilament light (NfL) levels (Hong et al., 2021).